- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05397184
Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (TvT CAR7)
Phase 1 Study of Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)
Study Overview
Status
Intervention / Treatment
Detailed Description
Who can participate? Patients aged 6 months to 16 years with relapsed/refractory T cell leukaemia ahead of a planned bone marrow transplant
What does the study involve? Patients will undergo careful screening to confirm that this treatment is adequate for them. Chemotherapy will be given prior to BE CAR-7 infusion to improve the ability of T-cells to establish and grow. Patients will then receive a single infusion of the BE CAR-7 cells and will be closely monitored in hospital. Patients are expected to be in hospital for 4-6 weeks for the BE CAR-7 treatment and the transplant will be scheduled 2-4 weeks after the end of BE CAR7 if leukaemia cells are no longer detectable. Patients will be monitored on the study for 1 year after transplant and then long term in routine clinics.
What are the possible benefits and risks of participating? Taking part in the study of testing 'ready-made' CAR T cells could help reduce the amount of disease and get the patient into remission before a bone marrow transplant. Leukaemia is less likely to come back after a bone marrow transplant if levels in the bone marrow are undetectable. The ready-made CAR T cells are being used to try and improve the chances of successful transplantation. Side effects may include low blood cell counts, infections, cytokine storm (severe immune reaction), graft versus host disease (where the donated cells attack the body) and other complications.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Robert Chiesa, Dr
- Phone Number: 8434 020 7405 9200
- Email: Robert.Chiesa@gosh.nhs.uk
Study Contact Backup
- Name: Agnieszka B Kubat, MSc
- Phone Number: 07502269573
- Email: a.kubat@ucl.ac.uk
Study Locations
-
-
-
London, United Kingdom, WC1N 1EH
- Recruiting
- Ilyas Ali
-
Contact:
- Ilyas Ali, MSc
- Phone Number: +44 (0)207 905 2863
- Email: Ilyas.Ali@gosh.nhs.uk
-
Contact:
- Vanshree Patel, Dr
- Phone Number: +44 (0)207 905 2863
- Email: Vanshree.Patel@gosh.nhs.uk
-
Principal Investigator:
- Waseem Qasim, Professor
-
Sub-Investigator:
- Robert Chiesa, Dr
-
Sub-Investigator:
- Ajay Vora, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Demographic characteristics:
- Male or female patients
- Age ranging between 6 months and <16 years
Medical and therapeutic criteria:
- Relapsed/refractory T cell malignancy ahead of planned allogeneic haematopoietic stem cell transplantation (allo-SCT). Morphologically confirmed with leukemic blasts in the bone marrow (>5%) or a quantifiable MRD load (by multiparameter flow cytometry and/or quantitative polymerase chain reaction)
- CD7+ (>99%) leukaemia associated immunophenotype (LAIP)
- Eligible and fit for allogeneic hematopoietic stem cells transplantation with suitable donor available
- Estimated life expectancy ≥12 weeks
- Lansky (age <16 years at the time of assent/consent) or Karnofsky (age ≥16 years at the time of assent/consent) performance status ≥70; Eastern Cooperative Oncology Group ECOG performance status < 2
Exclusion Criteria:
- Patients/parents unwilling to undergo a follow-up for 15 years
- Foreseeable poor compliance to the study procedures
- Evidence of disease progression after cytoreduction
- Uncontrollable CNS leukaemia or neurological symptoms defined as CNS grade 3 (per National Comprehensive Cancer Network guidelines)
- Absence of suitable HLA matched or mismatched donor
- Weight <6 kg
- Presence of donor-specific anti-HLA antibodies directed against BE-CAR7
- GvHD requiring systemic therapy
- Systemic steroid therapy prednisolone >0.5 mg/kg/day
- Known hypersensitivity to any of the test materials or related compounds
- Active bacterial, fungal or viral infection not controlled by standard of care anti-microbial or anti-viral treatment. Uncontrolled bacteraemia/ fungaemia is defined as the ongoing detection of bacteria/fungus on blood cultures despite antibiotic or antifungal therapy. Uncontrolled viraemia is defined as rising viral loads on two consecutive occasions despite antiviral therapy.
- Risk of pregnancy or non-compliance with contraception (if applicable). Girls of childbearing potential must have been tested negative in a pregnancy test within 14 days prior to inclusion.
- Lactating female participants unwilling to stop breastfeeding
- Prior CAR therapy known to be associated with ≥Grade 3 cytokine release syndrome (CRS) or ≥Grade 3 drug-related CNS toxicity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single-dose intravenous infusion of a banded dose of CAR7+ T cells/kg BECAR7
Single-dose intravenous infusion (weight-based dosing) of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months Patients will undergo careful screening to confirm that this treatment is adequate for them.
Chemotherapy will be given prior to BE CAR-7 infusion.
Patients will then receive a single infusion of the BE CAR-7 cells and will be closely monitored in hospital via blood and bone marrow tests for safety and to check the levels of BE CAR-7 and leukaemia cells.
Patients are expected to be in hospital for 4-6 weeks for the BE CAR-7 therapy and the transplant will be scheduled 2-4 weeks after the end of BE CAR7 if leukaemia cells are no longer detectable.
Patients will be monitored on the study for 1 year every month for the first 3 months and then every 6 months and then long term in routine clinics.
|
Single-dose intravenous infusion (weight-based dosing) of a banded dose of CAR7+ T cells/kg BECAR7 Total duration of treatment: 28 days Follow-up: 12 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and description of adverse events after BE-CAR7 infusion
Time Frame: 1 year
|
Incidence of Grade 3-5 toxicities occurring from infusion up to one year follow-up. Severe Adverse Reactions of special interest will be CRS, ICANS and GvHD. American Society of Bone Marrow Transplantation grading scales for CRS/ICANS and National Institute of Health criteria for GVHD will be applied. Commo Terminology Criteria nomenclature will be used to grade other adverse events. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients achieving disease remission ahead of allo-SCT
Time Frame: 28 days
|
Remission rate will be assessed by bone marrow and CNS evaluation after 28 days.
Disease remission is defined as morphological complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with MRD <10e-3 by flow and/or PCR.
|
28 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Waseem Qasim, Professor, Great Ormond Street Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19IC17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory T-cell Acute Lymphoid Leukaemia
-
Mundipharma Research LimitedInnovative Therapies For Children with Cancer ConsortiumTerminatedRelapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's LymphomaCzech Republic, Austria, France, Germany, Italy, United Kingdom
-
National University of MalaysiaGaia ScienceRecruitingRelapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic LeukaemiaMalaysia
-
Hospital Infantil Universitario Niño Jesús, Madrid...TerminatedRelapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and LymphomaSpain
-
Versailles HospitalRecruitingT-cell Acute Lymphoblastic Leukemia | Relapsed/Refractory Acute Lymphoblastic LeukemiaFrance
-
Therapeutic Advances in Childhood Leukemia ConsortiumGlaxoSmithKline; NovartisTerminatedRelapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic LymphomaUnited States, France, Canada, Australia, Austria, Italy, Netherlands
-
Juan C. Ramos, MDWithdrawnAcute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Refractory Leukemia | Adult T-Cell Leukemia/Lymphoma | Relapsed LeukemiaUnited States
-
King's College Hospital NHS TrustCompletedHTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)United Kingdom
-
SanofiTerminatedT-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/LeukaemiaHungary, United States, Finland, France, Italy, Lithuania, Russian Federation
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingMyeloid Malignancy | Relapsed/Refractory Acute Myeloid LeukaemiaChina
-
AstraZenecaCompletedRelapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins LymphomaItaly, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
Clinical Trials on Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL)
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
Medical College of WisconsinRecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)United States
-
Jeffrey BluestoneNational Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance...TerminatedAcute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoVUnited States
-
Wuerzburg University HospitalCompletedMyelodysplastic Syndromes | Leukemia, Myeloid, AcuteGermany
-
Wuhan Union Hospital, ChinaBeijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.RecruitingT-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin LymphomaChina
-
Hospital Israelita Albert EinsteinMiltenyi Biotec, Inc.Not yet recruitingAcute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia RefractoryBrazil
-
Memorial Sloan Kettering Cancer CenterOtsuka America Pharmaceutical; Ludwig Institute for Cancer ResearchCompleted